Literature DB >> 17228250

The dopaminergic nigrostriatal system and Parkinson's disease: molecular events in development, disease, and cell death, and new therapeutic strategies.

Mojgan Hodaie1, Joseph S Neimat, Andres M Lozano.   

Abstract

For several decades, the clinical study of Parkinson's disease has driven an increasingly sophisticated understanding of the dopaminergic system and its complex role in modulating motor behavior. This article reviews salient areas of research in this field, commencing with the molecular biology of the development of the mesencephalic dopaminergic system. We then discuss events thought to be crucial in the cellular and molecular pathology of Parkinson's disease, proposed mechanisms of cell death, and relevant toxin models. These advancements are used as a template to review emerging therapeutic techniques, including neuroprotection strategies, surgical treatment of trophic factors, gene therapy, and neural transplantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17228250     DOI: 10.1227/01.NEU.0000249209.11967.CB

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  19 in total

1.  Neurite orientation dispersion and density imaging in the substantia nigra in idiopathic Parkinson disease.

Authors:  Koji Kamagata; Taku Hatano; Ayami Okuzumi; Yumiko Motoi; Osamu Abe; Keigo Shimoji; Kouhei Kamiya; Michimasa Suzuki; Masaaki Hori; Kanako K Kumamaru; Nobutaka Hattori; Shigeki Aoki
Journal:  Eur Radiol       Date:  2015-10-29       Impact factor: 5.315

2.  The Ethics of the Treatment of Spinal Cord Injury: Stem Cell Transplants, Motor Neuroprosthetics, and Social Equity.

Authors:  Jeffrey V Rosenfeld; Prateek Bandopadhayay; Tony Goldschlager; Douglas J Brown
Journal:  Top Spinal Cord Inj Rehabil       Date:  2008

3.  Effects of aging on the ventral and dorsal substantia nigra using diffusion tensor imaging.

Authors:  David E Vaillancourt; Matthew B Spraker; Janey Prodoehl; Xiaohong Joe Zhou; Deborah M Little
Journal:  Neurobiol Aging       Date:  2010-03-31       Impact factor: 4.673

4.  Nitrated alpha-synuclein and microglial neuroregulatory activities.

Authors:  Ashley D Reynolds; Irena Kadiu; Sanjay K Garg; Jason G Glanzer; Tara Nordgren; Pawel Ciborowski; Ruma Banerjee; Howard E Gendelman
Journal:  J Neuroimmune Pharmacol       Date:  2008-01-17       Impact factor: 4.147

Review 5.  Immunology of neurological gene therapy: how T cells modulate viral vector-mediated therapeutic transgene expression through immunological synapses.

Authors:  Pedro R Lowenstein; Kurt Kroeger; Maria G Castro
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

6.  Chemical exchange saturation transfer MR imaging of Parkinson's disease at 3 Tesla.

Authors:  Chunmei Li; Shuai Peng; Rui Wang; Haibo Chen; Wen Su; Xuna Zhao; Jinyuan Zhou; Min Chen
Journal:  Eur Radiol       Date:  2014-07-20       Impact factor: 5.315

Review 7.  Resting state functional magnetic resonance imaging in Parkinson's disease.

Authors:  Janey Prodoehl; Roxana G Burciu; David E Vaillancourt
Journal:  Curr Neurol Neurosci Rep       Date:  2014-06       Impact factor: 5.081

Review 8.  Nicotine and Parkinson's disease: implications for therapy.

Authors:  Maryka Quik; Kathryn O'Leary; Caroline M Tanner
Journal:  Mov Disord       Date:  2008-09-15       Impact factor: 10.338

9.  A Comparative White Matter Study with Parkinson's disease, Parkinson's Disease with Dementia and Alzheimer's Disease.

Authors:  Rodrigo D Perea; Rebecca C Rada; Jessica Wilson; Eric D Vidoni1; Jill K Morris; Kelly E Lyons; Rajesh Pahwa; Jeffrey M Burns; Robyn A Honea
Journal:  J Alzheimers Dis Parkinsonism       Date:  2013-08-26

10.  High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease.

Authors:  D E Vaillancourt; M B Spraker; J Prodoehl; I Abraham; D M Corcos; X J Zhou; C L Comella; D M Little
Journal:  Neurology       Date:  2009-01-07       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.